{
    "clinical_study": {
        "@rank": "40196", 
        "arm_group": [
            {
                "arm_group_label": "Ticagrelor and Eptifibatide bolus", 
                "arm_group_type": "Active Comparator", 
                "description": "Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180\u00b5g/Kg each 10 min apart)"
            }, 
            {
                "arm_group_label": "Ticagrelor & Eptifibatide bolus+infusion", 
                "arm_group_type": "Active Comparator", 
                "description": "Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180\u00b5g/Kg, 10 min apart, followed by 2\u00b5g/Kg/min infusion for 2 hours)"
            }
        ], 
        "brief_summary": {
            "textblock": "This purpose of this study is to measure platelet response to ticagrelor and eptifibatide\n      bolus-only compared with ticagrelor and eptifibatide bolus plus 2-hour infusion\n      administrated after cardiac catheterization in patients undergoing non-emergent percutaneous\n      coronary intervention."
        }, 
        "brief_title": "Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Coronary Syndrome", 
        "condition_browse": {
            "mesh_term": "Acute Coronary Syndrome"
        }, 
        "detailed_description": {
            "textblock": "In this study, 60 patients with Acute Coronary Syndrome who are undergoing non-emergent\n      percutaneous coronary intervention (PCI) will be randomized to ticagrelor loading dose and\n      eptifibatide bolus-only versus ticagrelor loading dose and eptifibatide bolus plus 2 hour\n      infusion administrated after cardiac catheterization, but before PCI. Platelet function\n      testing will be performed at baseline and follow-up."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        For inclusion in the study subjects should fulfill the following criteria:\n\n          -  Provision of informed consent prior to any study specific procedures\n\n          -  Males and females aged 19 years and older\n\n          -  Congruent to the PLATO trial, at least two of the following three criteria have to be\n             met:\n\n          -  ST-segment changes on electrocardiography, indicating ischemia;\n\n          -  a positive test of a biomarker, indicating myocardial necrosis; or one of several\n             risk factors;\n\n          -  age >60 years\n\n          -  previous myocardial infarction or coronary-artery bypass grafting [CABG];\n\n          -  coronary artery disease with stenosis of \u226550% in at least two vessels;\n\n          -  previous ischemic stroke, transient ischemic attack, carotid stenosis of at least\n             50%, or cerebral revascularization;\n\n          -  diabetes mellitus;\n\n          -  peripheral arterial disease;\n\n          -  or chronic renal dysfunction, defined as a creatinine clearance of <60 ml per minute\n             per 1.73 m2 of body surface area).\n\n          -  patients with symptoms of unstable angina lasting \u226510 min and either an  elevated\n             troponin I level or newly developed ST-segment depression of 1 mm or transient\n             ST-segment elevation of 1 mm will also be included.\n\n        Exclusion Criteria:\n\n        Subjects should not enter the study if any of the following exclusion criteria are\n        fulfilled:\n\n          -  Patients with active pathological bleeding or a history of intracranial bleeding;\n\n          -  patients with planned to urgent coronary artery bypass graft surgery;\n\n          -  severe hepatic impairment;\n\n          -  concomitant therapy with a strong cytochrome P-450 3A inhibitors;\n\n          -  surgery<4 weeks;\n\n          -  the use of any thienopyridine (within the previous two weeks);\n\n          -  upstream use of GP IIb/IIIa inhibitors;\n\n          -  bleeding diathesis or major bleeding episode within 2 weeks;\n\n          -  a need for oral anticoagulation therapy;\n\n          -  thrombocytopenia;\n\n          -  presence of thrombus in the coronary artery; incessant chest pain or hemodynamic\n             instability;\n\n          -  and patients with GFR<30 mL/min or on hemodialysis.\n\n          -  maintenance dose of aspirin above 100mg\n\n          -  history of allergies to Ticagrelor\n\n          -  patients at increased risk of bradycardic events (e.g., patients who have sick sinus\n             syndrome, 2nd or 3rd degree AV block, or bradycardic related syncope and not\n             protected with a pacemaker\n\n          -  women who are pregnant or breastfeeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01919723", 
            "org_study_id": "ISSBRIL0077"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Ticagrelor and Eptifibatide bolus", 
                    "Ticagrelor & Eptifibatide bolus+infusion"
                ], 
                "description": "ticagrelor loading dose", 
                "intervention_name": "ticagrelor", 
                "intervention_type": "Drug", 
                "other_name": "brilinta"
            }, 
            {
                "arm_group_label": [
                    "Ticagrelor and Eptifibatide bolus", 
                    "Ticagrelor & Eptifibatide bolus+infusion"
                ], 
                "description": "i.v. infusion", 
                "intervention_name": "Eptifibatide", 
                "intervention_type": "Drug", 
                "other_name": "integrilin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Eptifibatide", 
                "Ticagrelor"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "PCI", 
            "Ticagrelor", 
            "Eptifibatide"
        ], 
        "lastchanged_date": "March 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294"
                    }, 
                    "name": "University of Alabama"
                }, 
                "investigator": {
                    "last_name": "Massoud Leesar, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "conwaygg@ucmail.uc.edu", 
                    "last_name": "Ginger Conway, MSN, RN", 
                    "phone": "513-558-3476"
                }, 
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45267"
                    }, 
                    "name": "University of Cincinnati"
                }, 
                "investigator": {
                    "last_name": "Mohamed A Effat, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Pharmacodynamic Effects of Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion in Patients Undergoing Percutaneous Coronary Intervention", 
        "other_outcome": {
            "description": "Comparison of bleeding complications in patients randomized to ticagrelor and 2 boluses of eptifibatide with ticagrelor and 2 boluses plus 2-h infusion of eptifibatide.", 
            "measure": "Comparison of bleeding complications", 
            "safety_issue": "Yes", 
            "time_frame": "Comparing baseline and follow-up (18 hours)"
        }, 
        "overall_contact": {
            "email": "jharsh@uab.edu", 
            "last_name": "Joan Harshberger, RN", 
            "phone": "205-975-9426"
        }, 
        "overall_official": {
            "affiliation": "University of Alabama at Birmingham", 
            "last_name": "Massoud Leesar, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change from baseline in percent inhibition of platelet activity (%IPA) at 6 hours measured in the blood by an aggregomter among patients randomized to ticagrelor and 2 boluses of eptifibatide vs. ticagrelor and 2 boluses plus infusion of eptifibatide.", 
            "measure": "Change in percent inhibition of platelet activity", 
            "safety_issue": "No", 
            "time_frame": "Comparing baseline with follow-up (6 hours)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01919723"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Correlations between the percent inhibition of platelet activity (% IPA) in the blood measured by an aggregomter after exposure of blood to agonists such as adenosine diphosphate versus thrombin receptor agonist peptide.", 
            "measure": "Correlations between platelet activity inhibition", 
            "safety_issue": "No", 
            "time_frame": "Comparing baseline and follow-up (6 hours)"
        }, 
        "source": "University of Alabama at Birmingham", 
        "sponsors": {
            "collaborator": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of Alabama at Birmingham", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}